HealthPhoto: Business StandardBharat Biotech Subsidiary Partners with VeGen Bio for Cancer Therapy
Bharat Biotech's subsidiary Nucelion Therapeutics has partnered with Hyderabad-based VeGen Bio to manufacture an advanced CAR-T therapy, VL-2511, targeting multiple myeloma. Nucelion will handle technology transfer, process development, and manufacturing at its Hyderabad facility. The therapy aims for Phase 1/2 clinical trials in India and potential commercialization by 2028, pending regulatory approval. This partnership focuses on manufacturing, not marketing.
Business Standard··Hyderabad


